Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2016 Dec 8;59(6):559–568. doi: 10.1007/s12374-016-0482-9

Potential of plants to produce recombinant protein products

Ky Young Park 1, Soo Jin Wi 1,✉
PMCID: PMC7101786  PMID: 32288513

Abstract

Plants have great potential as photosynthetic factories to produce pharmaceutically important and commercially valuable biomedicines and industrial proteins at low cost. The U.S. Food and Drug Administration (U.S. FDA) has approved the drug Elelyso (taliglucerase alfa) produced by carrot cells for treatment of type 1 Gaucher’s disease in 2012. The commercial potential of biomedicines produced by molecular farming has dramatically improved due to the success of an experimental drug called ZMapp, which has immunological activity in Ebola patients. A cocktail of three monoclonal antibodies was produced in tobacco (Nicotiana benthamiana) plants (Chen and Davis 2016). At present, very few drugs made by this technology have been approved by worldwide authorities such as the U.S. FDA. However, plants have been proposed as a novel paradigm for commercial production of proteins over the next decade. In recent years, leading researchers on molecular farming have given more priority to the area of animal-free therapeutic proteins such as parenteral and oral vaccines. Although plant-based platforms have considerable advantages over traditional systems such as bacterial and animal systems, there are several obstacles to commercial-scale production, especially with regards to improving the quality and quantity of plant-produced biologics and industrial materials. One of the biggest barriers to commercialization of this technology is the intense scrutiny of these new plant varieties by regulatory agencies and the public as well as the high costs associated with their regulatory approval.

Keywords: Pharmaceutical, Plant-made recombinant protein, Plant molecular farming, Public, Regulatory agency

References

  1. Abiri R, Valdiani A, Maziah M, Shaharuddin NA, Sahebi M, Yusof ZNB, Atabaki N, Tale D. A critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming. Curr Issues Mol Biol. 2015;18:21–42. [PubMed] [Google Scholar]
  2. Bakker H, Rouwendal GJ, Karnoup AS, Florack DE, Stoopen GM, Helsper JP, van Ree R, van Die I, Bosch D. An antibody produced in tobacco expressing a hybrid b-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes. Proc Natl Acad Sci USA. 2006;103:7577–7582. doi: 10.1073/pnas.0600879103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Broz A, Huang N, Unruh G. Plant-based protein biomanufacturing. 2013. [Google Scholar]
  4. Chen Q, Davis KR. The potential of plants as a system for the development and production of human biologics. 2016;5:912. doi: 10.12688/f1000research.8010.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, Black A, Passmore D, Moldovan-Loomis C, Srinivasan M, Cuison S, Cardarelli PM, Dickey LF. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol. 2006;24:1591–1597. doi: 10.1038/nbt1260. [DOI] [PubMed] [Google Scholar]
  6. Dugdale B, Mortimer CL, Kato M, James TA, Harding RM, Dale JL. In plant activation: an inducible, hyperexpression platform for recombinant protein production in plants. Plant Cell. 2013;25:2429–2443. doi: 10.1105/tpc.113.113944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Farran I S-S, Medina JF, Prieto J, Mingo-Castel AM. Targeted expression of human serum albumin to potato tubers. Transgenic Res. 2002;11:337–346. doi: 10.1023/A:1016356510770. [DOI] [PubMed] [Google Scholar]
  8. Faye L, Boulaflous A, Benchabane M, Gomord V, Michaud D. Protein modifications in the plant secretory pathway: current status and practical implications in molecular pharming. Vaccine. 2005;23:1770–1778. doi: 10.1016/j.vaccine.2004.11.003. [DOI] [PubMed] [Google Scholar]
  9. Fischer R, Schillberg S, Buyel JF, Twyman RM. Commercial aspects of pharmaceutical protein production in plants. Curr Pharm Des. 2013;19:5471–5477. doi: 10.2174/1381612811319310002. [DOI] [PubMed] [Google Scholar]
  10. Gleba Y, Klimyuk V, Marillonnet S. Viral vectors for the expression of proteins in plants. Curr Opin Biotech. 2007;18:134–141. doi: 10.1016/j.copbio.2007.03.002. [DOI] [PubMed] [Google Scholar]
  11. Healy M (2014) U.S. seeks to speed up production of Ebola drug. LA Times 2014.9.2
  12. Hefferon KL. Plant virus expression vectors set the stage as production platforms for biopharmaceutical proteins. Virology. 2012;433:1–6. doi: 10.1016/j.virol.2012.06.012. [DOI] [PubMed] [Google Scholar]
  13. Hood EE. From green plants to industrial enzymes. Enzyme Microb Tech. 2002;30:279–283. doi: 10.1016/S0141-0229(01)00502-6. [DOI] [Google Scholar]
  14. Hood EE, Howard JA. Commercial plant-produced recombinant avidin. In: Howard JA, Hood EE, editors. Commercial plantproduced recombinant protein products. 2014. pp. 15–25. [Google Scholar]
  15. Howard JA, Christon P. Introduction: Plant-produced protein products. In: Howard JA, Hood EE, editors. Commercial plantproduced recombinant protein products. 2014. pp. 1–11. [Google Scholar]
  16. Jouzani GS, Tohidfar M. Plant molecular farming: Future prospects and biosafety challenges. Biosafety. 2013;2:e136. doi: 10.4172/2167-0331.1000e136. [DOI] [Google Scholar]
  17. Lee SW. Current status on the development and commercialization of GM plants. J Plant Biotechnol. 2010;37:305–312. doi: 10.5010/JPB.2010.37.3.305. [DOI] [Google Scholar]
  18. Lyon K. LeafBio announces conclusion of ZMapp™ clinical Trial. Therapy to treat ebola shows promise. 2016. [Google Scholar]
  19. MacDonald J, Doshi K, Dussault M, Hall JC, Holbrook L, Jones G, Kaldis A, Klima CL, Macdonald P, McAllister T, McLean MD, Potter A, Richman A, Shearer H, Yarosh O, Yoo HS, Topp E, Menassa R. Bringing plant-based veterinary vaccines to market: Managing regulatory and commercial hurdles. Biotechnol Adv. 2015;33:1572–1581. doi: 10.1016/j.biotechadv.2015.07.007. [DOI] [PubMed] [Google Scholar]
  20. Malabadi RB, Chalannavar RK, Meti NT, Gani RS, Vijayakumar S, Mulgund SS, Masti S, Chougale R, Odhav B, Sowmyashree K, Supriya S, Nityasree BR, Divakar MS. Insulin plant, costus speciosus: ethnobotany and pharmacological updates. Int J Curr Res Biosci Plant Biol. 2016;3:151–161. doi: 10.20546/ijcrbp.2016.307.021. [DOI] [Google Scholar]
  21. Paul M, Ma JKC. Plant-made pharmaceuticals: Leading products and production platforms. Biotechnol Appl Bioc. 2011;58:58–67. doi: 10.1002/bab.6. [DOI] [PubMed] [Google Scholar]
  22. Paul MJ, Thangaraj H, Ma JK. Commercialization of new biotechnology: a systematic review of 16 commercial case studies in a novel manufacturing sector. Plant Biotechnol J. 2015;13:1209–1920. doi: 10.1111/pbi.12426. [DOI] [PubMed] [Google Scholar]
  23. Rosales-Mendoza S, Angulo C, Meza B. Food-grade organisms as vaccine biofactories and oral delivery vehicles. Trends Biotechnol. 2016;34:124–136. doi: 10.1016/j.tibtech.2015.11.007. [DOI] [PubMed] [Google Scholar]
  24. Rybicki EP, Chikwamba R, Koch M, Rhodes JI, Groenewald JH. Plant-made therapeutics: an emerging platform in South Africa. Biotechnol Adv. 2012;30:449–459. doi: 10.1016/j.biotechadv.2011.07.014. [DOI] [PubMed] [Google Scholar]
  25. Sack M, Hofbauer A, Fischer R, Stoger E. The increasing value of plant-made proteins. Curr Opin Biothech. 2015;32:163–170. doi: 10.1016/j.copbio.2014.12.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum S, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J. 2007;5:579–590. doi: 10.1111/j.1467-7652.2007.00263.x. [DOI] [PubMed] [Google Scholar]
  27. Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, Mett V, Musiychuk K, Bi H, Farrance C, Shamloul M, Kushnir N, Sharma S, Yusibov V. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin. 2011;7:41–50. doi: 10.4161/hv.7.0.14561. [DOI] [PubMed] [Google Scholar]
  28. Sparrow P, Broer I, Hood EE, Eversole K, Hartung F, Schiemann J. Risk assessment and regulation of molecular farming -a comparison between Europe and US. Curr Pharm Des. 2013;19:5513–5530. doi: 10.2174/1381612811319310007. [DOI] [PubMed] [Google Scholar]
  29. Strasser R, Altmann F, Steinkellner H. Controlled glycosylation of plant-produced recombinant proteins. Curr Opin Biothech. 2014;30:95–100. doi: 10.1016/j.copbio.2014.06.008. [DOI] [PubMed] [Google Scholar]
  30. Sylvester AW, Lewis RV, David Jackson D (2011) Patent No. U.S. 8993844 B1 Production of spider silk protein in corn
  31. Topp E, Irwin R, McAllister T, Lessard M, Joensuu JJ, Kolotilin I, Conrad U, Stöger E, Mor T, Warzecha H, Hall JC, McLean MD, Cox E, Devriendt B, Potter A, Depicker A, Virdi V, Holbrook L, Doshi K, Dussault M, Friendship R, Yarosh O, Yoo HS, MacDonald J, Menassa R. The case for plant-made veterinary immunotherapeutics. Biotechnol Adv. 2016;34:597–604. doi: 10.1016/j.biotechadv.2016.02.007. [DOI] [PubMed] [Google Scholar]
  32. Tschofen M, Knopp D, Hood E, Stoge E. Plant molecular farming: Much more than medicines. Annu Rev Anal Chem. 2016;9:271–294. doi: 10.1146/annurev-anchem-071015-041706. [DOI] [PubMed] [Google Scholar]
  33. Tusé D, Tu T, McDonald KA. Biomed Res Int. 2014. Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Twyman RM, Stöger E, Schillberg S, Christou P, Fischer R. Molecular farming in plants: host systems and expression technology. Trends Biotechnol. 2003;21:570–578. doi: 10.1016/j.tibtech.2003.10.002. [DOI] [PubMed] [Google Scholar]
  35. Wang YC, Peterson SE, Loring JF. Protein post-translational modifications and regulation of pluripotency in human stem cells. Cell Res. 2014;24:143–160. doi: 10.1038/cr.2013.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Werner S, Breus O, Symonenko Y, Marillonnet S, Gleba Y. High-level recombinant protein expression in transgenic plants by using a double-inducible viral vector. Proc Natl Acad Sci USA. 2011;108:14061–14066. doi: 10.1073/pnas.1102928108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Xu J, Dolan MC, Medrano G, Cramer CL, Weathers PJ. Green factory: Plants as bioproduction platforms for recombinant proteins. Biotechnol Adv. 2012;30:1171–1184. doi: 10.1016/j.biotechadv.2011.08.020. [DOI] [PubMed] [Google Scholar]
  38. Yamanaka T, Ohta T, Takahashi M, Meshi T, Schmidt R, Dean C, Naito S, Ishikawa M. TOM1, an Arabidopsis gene required for efficient multiplication of a tobamovirus, encodes a putative transmembrane protein. Proc Natl Acad Sci USA. 2000;97:10107–10112. doi: 10.1073/pnas.170295097. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Plant Biology = Singmul Hakhoe Chi are provided here courtesy of Nature Publishing Group

RESOURCES